APA
Click to copy
Vijayakumar, A., Majumder, M., Yin, S., Brobbey, C., Karam, J., Howley, B., … Palanisamy, V. (2024). PRMT5-mediated arginine methylation of FXR1 is essential for RNA binding in cancer cells. Nucleic Acids Research.
Chicago/Turabian
Click to copy
Vijayakumar, Anitha, Mrinmoyee Majumder, Shasha Yin, Charles Brobbey, Joseph Karam, B. Howley, Philip H Howe, et al. “PRMT5-Mediated Arginine Methylation of FXR1 Is Essential for RNA Binding in Cancer Cells.” Nucleic Acids Research (2024).
MLA
Click to copy
Vijayakumar, Anitha, et al. “PRMT5-Mediated Arginine Methylation of FXR1 Is Essential for RNA Binding in Cancer Cells.” Nucleic Acids Research, 2024.
BibTeX Click to copy
@article{anitha2024a,
title = {PRMT5-mediated arginine methylation of FXR1 is essential for RNA binding in cancer cells.},
year = {2024},
journal = {Nucleic Acids Research},
author = {Vijayakumar, Anitha and Majumder, Mrinmoyee and Yin, Shasha and Brobbey, Charles and Karam, Joseph and Howley, B. and Howe, Philip H and Berto, Stefano and Madan, Lalima K. and Gan, Wenjian and Palanisamy, Viswanathan}
}
Emerging evidence indicates that arginine methylation promotes the stability of arginine-glycine-rich (RGG) motif-containing RNA-binding proteins (RBPs) and regulates gene expression. Here, we report that post-translational modification of FXR1 enhances the binding with mRNAs and is involved in cancer cell growth and proliferation. Independent point mutations in arginine residues of FXR1's nuclear export signal (R386 and R388) and RGG (R453, R455 and R459) domains prevent it from binding to RNAs that form G-quadruplex (G4) RNA structures. Disruption of G4-RNA structures by lithium chloride failed to bind with FXR1, indicating its preference for G4-RNA structure containing mRNAs. Furthermore, loss-of-function of PRMT5 inhibited FXR1 methylation both in vivo and in vitro, affecting FXR1 protein stability, inhibiting RNA-binding activity and cancer cell growth and proliferation. Finally, the enhanced crosslinking and immunoprecipitation (eCLIP) analyses reveal that FXR1 binds with the G4-enriched mRNA targets such as AHNAK, MAP1B, AHNAK2, HUWE1, DYNC1H1 and UBR4 and controls its mRNA expression in cancer cells. Our findings suggest that PRMT5-mediated FXR1 methylation is required for RNA/G4-RNA binding, which promotes gene expression in cancer cells. Thus, FXR1's structural characteristics and affinity for RNAs preferentially G4 regions provide new insights into the molecular mechanism of FXR1 in oral cancer cells.
